In a clinically relevant setting, we moreover demonstrate that treatment of breast cancer cells with suboptimal doses of these HER2-targeting drugs consistently results in selection of cells with upregulated IRS4-levels, in particular with Lapatinib. This evidence concerns the gene IRS4 and breast carcinoma.